Celularity (NASDAQ:CELU) Trading 0.4% Higher - Should You Buy?

Celularity, Inc. (NASDAQ:CELU - Get Free Report) shares were up 0.4% on Friday . The company traded as high as $2.01 and last traded at $1.98. Approximately 50,278 shares were traded during trading, a decline of 20% from the average daily volume of 62,705 shares. The stock had previously closed at $1.9730.Wall Street Analysts Forecast GrowthA number of equities analysts recently issued reports on CELU shares. Wall Street Zen downgraded shares of Celularity from a "hold" rating to a "sell" rating in a research note on Friday, September 5th. WBB Securities raised Celularity from a "hold" rating to a "buy" rating and set a $6.00 target price for the company in a research report on Tuesday, September 9th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Celularity in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $6.00.Check Out Our Latest Report on CELUCelularity Price PerformanceThe stock's 50 day simple moving average is $1.93 and its two-hundred day simple moving average is $2.35. The firm has a market cap of $56.09 million, a P/E ratio of -0.59 and a beta of 0.77. Celularity (NASDAQ:CELU - Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($1.50) by $0.62. Celularity had a negative return on equity of 459.57% and a negative net margin of 198.75%.The company had revenue of $5.28 million for the quarter. Hedge Funds Weigh In On CelularityA number of hedge funds have recently bought and sold shares of the company. Perennial Investment Advisors LLC bought a new stake in Celularity during the 3rd quarter valued at about $28,000. Acadian Asset Management LLC purchased a new stake in shares of Celularity during the first quarter valued at approximately $34,000. XTX Topco Ltd increased its position in shares of Celularity by 106.4% during the second quarter. XTX Topco Ltd now owns 21,452 shares of the company's stock valued at $42,000 after acquiring an additional 11,057 shares in the last quarter. Bank of America Corp DE raised its holdings in Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company's stock worth $73,000 after acquiring an additional 35,023 shares during the last quarter. Finally, HB Wealth Management LLC bought a new position in Celularity in the 3rd quarter valued at approximately $84,000. Institutional investors own 19.02% of the company's stock. Celularity Company Profile (Get Free Report)Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.Featured ArticlesFive stocks we like better than CelularityP/E Ratio Calculation: How to Assess StocksRocket Lab’s Big Rebound? Analysts Suggest the Dip's a GiftBank Stocks - Best Bank Stocks to Invest InMeta’s AI Moment? New SAM 3 Model Has Wall Street Turning BullishBest Stocks Under $10.00 Snowflake Stock: The Dip That Smart Investors Are Buying Right NowThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Celularity Right Now?Before you consider Celularity, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celularity wasn't on the list.While Celularity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here